ArticleTurkish journal of medical sciences2019
Branch retinal vein occlusion associated with platelet activation
Article in Turkish journal of medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Prognosis and factors related to anti-VEGF therapy in patients with retinal vein occlusion and concomitant carotid artery disease.Scientific reports · 2024Article
- Effect of plateletcrit and methylenetetrahydrofolate reductase (MTHFR) C677T genotypes on folic acid efficacy in stroke prevention.Signal transduction and targeted therapy · 2024Article
- The role of serum metrics in anti- VEGF treatment for macular edema induced by retinal vein occlusion.BMC ophthalmology · 2023Article
- Platelet-Derived Procoagulant Microvesicles Are Elevated in Patients with Retinal Vein Occlusion (RVO).Journal of clinical medicine · 2022Article
- Complete Blood Count-Derived Inflammation Indices and Retinal Vein Occlusion: A Case-Control Study.Ophthalmology and therapy · 2022Article
- Central retinal vein occlusion associated with platelet activation.Therapeutic advances in ophthalmologyArticle
- Systemic antiplatelet agents and anticoagulants in eyes with branch retinal vein occlusion.Therapeutic advances in ophthalmologyArticle
- Assessment of platelet-to-lymphocyte ratio in patients with retinal vein occlusion.Therapeutic advances in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: The aim of this study is to study subclinical platelet activation by detecting three important platelet activation parameters of mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT) in patients with branch retinal vein occlusion (BRVO) in comparison to those in healthy control subjects. Materials and methods: This prospective study included 43 patients with BRVO (Group 1)and 40 control subjects (Group 2). The levels of MPV, PDW, and PCT were measured in both of the studied groups Results: The mean serum level of MPV value was 7.64 ± 0.64 in Group 1 and 7.39 ± 0.42 in Group 2. Mean serum level of PDW was 15.01 ± 1.56 in Group 1 and 14.43 ± 1.03 in Group 2. Mean serum PCT value was 0.19 ± 0.05 in Group 1 and 0.16 ± 0.04 in Group 2. MPV, PDW, and PCT levels were significantly increased in BRVO patients (P < 0.05). Conclusion: Subclinical platelet activation reflected by MPV, PDW, and PCT may have an impact on the genesis of vessel occlusion in BRVO. The results may be important for the clinical management of patients with BRVO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.